Literature DB >> 1670995

Allelotype study of primary hepatocellular carcinoma.

M Fujimori1, T Tokino, O Hino, T Kitagawa, T Imamura, E Okamoto, M Mitsunobu, T Ishikawa, H Nakagama, H Harada.   

Abstract

Accumulation of mutations in oncogenes and tumor suppressor genes transforms a normal cell to a malignant cell by allowing it to escape from normal control of growth. In order to learn (a) how many tumor suppressor genes are involved in the tumor progression of hepatocellular carcinoma, (b) whether there is any association among allelic losses of chromosomes, or (c) whether integration of hepatitis B virus into host DNA influences any particular chromosomal losses, we have examined loss of heterozygosity with 44 restriction fragment length polymorphism markers in 46 cases of hepatocellular carcinoma. The markers represented all chromosomal arms except 5p, 8p, 9p, 18p, and acrocentric chromosomes. Allelic losses in tumors indicated that five tumor suppressor genes, located on chromosomes 5q, 10q, 11p, 16q, and 17p, may be involved in this cancer. However, no significant associations were observed among the various allelic losses or between the integration of hepatitis B virus and chromosomal losses. Furthermore, a deletion map for chromosome 16q indicated the localization of a tumor suppressor gene between q22 and q24 and that for chromosome 17p suggested the existence of a second tumor suppressor gene in addition to the p53 gene.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1670995

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  54 in total

1.  Mapping of 262 DNA markers into 24 intervals on human chromosome 11.

Authors:  A Tanigami; T Tokino; S Takiguchi; M Mori; T Glaser; J W Park; C Jones; Y Nakamura
Journal:  Am J Hum Genet       Date:  1992-01       Impact factor: 11.025

2.  Beta-catenin mutations are frequent in human hepatocellular carcinomas associated with hepatitis C virus infection.

Authors:  H Huang; H Fujii; A Sankila; B M Mahler-Araujo; M Matsuda; G Cathomas; H Ohgaki
Journal:  Am J Pathol       Date:  1999-12       Impact factor: 4.307

3.  Loss of heterozygosity of the retinoblastoma gene in liver cirrhosis accompanying hepatocellular carcinoma.

Authors:  K Ashida; Y Kishimoto; K Nakamoto; K Wada; G Shiota; Y Hirooka; Y Kamisaki; T Itoh; H Kawasaki
Journal:  J Cancer Res Clin Oncol       Date:  1997       Impact factor: 4.553

4.  Characterization of the human p57KIP2 gene: alternative splicing, insertion/deletion polymorphisms in VNTR sequences in the coding region, and mutational analysis.

Authors:  T Tokino; T Urano; T Furuhata; M Matsushima; T Miyatsu; S Sasaki; Y Nakamura
Journal:  Hum Genet       Date:  1996-05       Impact factor: 4.132

5.  Tumor suppress genes screening analysis on 4q in sporadic colorectal carcinoma.

Authors:  Li-Xin Jiang; Jie Xu; Zhao-Wen Wang; Da-Peng Li; Zhi-Hai Peng; Jian-Jun Gao; Lin He; Hai-Tao Zheng
Journal:  World J Gastroenterol       Date:  2008-09-28       Impact factor: 5.742

6.  Fragile histidine triad gene alterations are not essential for hepatocellular carcinoma development in South Korea.

Authors:  Chang-Woo Nam; Jung-Woo Shin; Neung-Hwa Park
Journal:  World J Gastroenterol       Date:  2008-06-14       Impact factor: 5.742

Review 7.  Genetic alterations in glioma and medulloblastoma.

Authors:  B K Rasheed; S H Bigner
Journal:  Cancer Metastasis Rev       Date:  1991-12       Impact factor: 9.264

Review 8.  Hepatocarcinogenesis in rodents and humans.

Authors:  T Kitagawa; K Miyasaka; H Kanda; H Yasui; O Hino
Journal:  J Cancer Res Clin Oncol       Date:  1995       Impact factor: 4.553

Review 9.  The adenomatous polyposis coli gene and human cancers.

Authors:  Y Nakamura
Journal:  J Cancer Res Clin Oncol       Date:  1995       Impact factor: 4.553

10.  pRb2/p130 protein expression and RBL2 mutation analysis in Burkitt lymphoma from Uganda.

Authors:  Sam Kalungi; Solrun J Steine; Henry Wabinga; Leif Bostad; Anders Molven
Journal:  BMC Clin Pathol       Date:  2009-08-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.